33 An international phase III RCT (RESOLVE-IT, NCT02704403) comparing elafibranor with placebo in NASH patients was terminated early due to insignificant efficacy but without significant adverse events at 72 weeks of treatment
Our board-certified physician will consider various factors, including your overall health, medical history, and weight loss goals in customizing a plan for you
405 The SURMOUNT-2 trial, a separate phase III trial conducted in seven countries, randomized 938 adults with type 2 diabetes and a BMI 27 kg/m 2 to receive tirzepatide (10 mg or 15 mg) or placebo once-weekly for 72 weeks
and Rybelsus as an oral option for type 2 diabetes
You'll get personalized guidance to restart your weight-loss progress without the trial-and-error that wastes precious time and motivation
During these consultations, patients have the opportunity to discuss their goals, learn more about available treatments, and receive personalized recommendations from Nurse Practitioner Swope